Mezzion Pharma Co.Ltd
Mezzion Pharma Co.,Ltd. engages in the development, licensing, and commercialization of drugs for the treatment of vascular diseases. It is developing Udenafil, a PDE5 inhibitor to treat erectile dysfunction, benign prostatic hyperplasia, pulmonary arterial hypertension, overactive bladder, hepatic portal hypertension, and chronic obstructive pulmonary diseases. The company was formerly known as … Read more
Mezzion Pharma Co.Ltd (140410) - Net Assets
Latest net assets as of September 2025: ₩37.35 Billion KRW
Based on the latest financial reports, Mezzion Pharma Co.Ltd (140410) has net assets worth ₩37.35 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩87.88 Billion) and total liabilities (₩50.54 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩37.35 Billion |
| % of Total Assets | 42.49% |
| Annual Growth Rate | -2.62% |
| 5-Year Change | -18.92% |
| 10-Year Change | -26.34% |
| Growth Volatility | 48.75 |
Mezzion Pharma Co.Ltd - Net Assets Trend (2012–2024)
This chart illustrates how Mezzion Pharma Co.Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mezzion Pharma Co.Ltd (2012–2024)
The table below shows the annual net assets of Mezzion Pharma Co.Ltd from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩46.06 Billion | -25.03% |
| 2023-12-31 | ₩61.44 Billion | +134.16% |
| 2022-12-31 | ₩26.24 Billion | -58.21% |
| 2021-12-31 | ₩62.79 Billion | +10.53% |
| 2020-12-31 | ₩56.81 Billion | +32.64% |
| 2019-12-31 | ₩42.83 Billion | -25.28% |
| 2018-12-31 | ₩57.32 Billion | +7.80% |
| 2017-12-31 | ₩53.17 Billion | +0.68% |
| 2016-12-31 | ₩52.81 Billion | -15.55% |
| 2015-12-31 | ₩62.54 Billion | -1.26% |
| 2012-12-31 | ₩63.34 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mezzion Pharma Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 759.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩14.98 Billion | 32.52% |
| Other Components | ₩174.23 Billion | 378.25% |
| Total Equity | ₩46.06 Billion | 100.00% |
Mezzion Pharma Co.Ltd Competitors by Market Cap
The table below lists competitors of Mezzion Pharma Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chongqing Fuling Zhacai Group Co Ltd
SHE:002507
|
$1.27 Billion |
|
NGL Energy Partners LP
NYSE:NGL
|
$1.27 Billion |
|
Beijing Venustech Inc
SHE:002439
|
$1.27 Billion |
|
Simply Good Foods Co
NASDAQ:SMPL
|
$1.27 Billion |
|
Ora Banda Mining Ltd
AU:OBM
|
$1.27 Billion |
|
Shenzhen Dynanonic Co Ltd
SHE:300769
|
$1.27 Billion |
|
Playa Hotels & Resorts BV
NASDAQ:PLYA
|
$1.27 Billion |
|
HBIS Co Ltd
SHE:000709
|
$1.27 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mezzion Pharma Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 61,444,362,860 to 46,062,511,800, a change of -15,381,851,060 (-25.0%).
- Net loss of 19,476,774,570 reduced equity.
- Share repurchases of 1,726,332,230 reduced equity.
- New share issuances of 1,726,332,220 increased equity.
- Other factors increased equity by 4,094,923,520.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-19.48 Billion | -42.28% |
| Share Repurchases | ₩1.73 Billion | -3.75% |
| Share Issuances | ₩1.73 Billion | +3.75% |
| Other Changes | ₩4.09 Billion | +8.89% |
| Total Change | ₩- | -25.03% |
Book Value vs Market Value Analysis
This analysis compares Mezzion Pharma Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 58.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 37.35x to 58.02x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩2388.50 | ₩89200.00 | x |
| 2017-12-31 | ₩2233.74 | ₩89200.00 | x |
| 2018-12-31 | ₩2225.90 | ₩89200.00 | x |
| 2019-12-31 | ₩1639.86 | ₩89200.00 | x |
| 2020-12-31 | ₩2129.43 | ₩89200.00 | x |
| 2021-12-31 | ₩2351.53 | ₩89200.00 | x |
| 2022-12-31 | ₩981.23 | ₩89200.00 | x |
| 2023-12-31 | ₩2076.71 | ₩89200.00 | x |
| 2024-12-31 | ₩1537.30 | ₩89200.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mezzion Pharma Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -42.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -226.17%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 1.61x
- Recent ROE (-42.28%) is below the historical average (-34.24%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 3.77% | 27.75% | 0.13x | 1.06x | ₩-3.95 Billion |
| 2015 | 6.75% | 28.29% | 0.14x | 1.65x | ₩-2.03 Billion |
| 2016 | -24.59% | -148.38% | 0.09x | 1.82x | ₩-18.27 Billion |
| 2017 | -27.99% | -266.42% | 0.08x | 1.39x | ₩-20.20 Billion |
| 2018 | -32.93% | -98.89% | 0.25x | 1.31x | ₩-24.61 Billion |
| 2019 | -54.29% | -122.82% | 0.32x | 1.37x | ₩-27.53 Billion |
| 2020 | -24.34% | -48.30% | 0.38x | 1.33x | ₩-19.51 Billion |
| 2021 | -21.66% | -51.03% | 0.32x | 1.34x | ₩-19.88 Billion |
| 2022 | -138.33% | -118.13% | 0.57x | 2.06x | ₩-38.92 Billion |
| 2023 | -20.72% | -40.13% | 0.34x | 1.50x | ₩-18.87 Billion |
| 2024 | -42.28% | -226.17% | 0.12x | 1.61x | ₩-24.08 Billion |
Industry Comparison
This section compares Mezzion Pharma Co.Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $96,196,506,488
- Average return on equity (ROE) among peers: -9.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mezzion Pharma Co.Ltd (140410) | ₩37.35 Billion | 3.77% | 1.35x | $1.27 Billion |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $3.69 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $94.65 Billion | 9.66% | 0.53x | $57.77 Million |
| NatureCell Co.Ltd (007390) | $34.02 Billion | -9.48% | 0.55x | $37.82 Million |
| Sam-A Pharm. Co. Ltd (009300) | $148.92 Billion | 6.63% | 0.09x | $21.27 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $257.20 Billion | 4.73% | 0.21x | $50.06 Million |
| WooGene B&G Co. Ltd (018620) | $26.51 Billion | -25.02% | 1.26x | $10.61 Million |
| Oscotec Inc (039200) | $28.83 Billion | -91.10% | 0.70x | $890.75 Million |
| EstechPharma Co. Ltd (041910) | $123.30 Billion | 5.58% | 0.09x | $50.99 Million |
| Komipharm International Co. Ltd (041960) | $93.39 Billion | -15.32% | 0.50x | $237.27 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $40.83 Billion | 8.91% | 0.29x | $20.48 Million |